Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers have presented findings from the first large cohort of people followed over a lengthy period to assess this connection.
Alert comes after 63 reports of such outcomes, largely in people who should not have received Mavyret, Zepatier or Vosevi.
Paying tribute to a courageous hepatitis C Warrior, Suzanne.
An honest look at what it feels like to live with advanced liver disease.
Researchers analyzed health data regarding modern hep C treatments specific to New South Wales.
Curing the virus was associated with a lower risk of liver cancer recurrence.
Hepatitis C patients who have cirrhosis are at risk for complications such as portal hypertension, ascites, cancer and other conditions.
Karen reaches out to her readers who are denied for the liver transplant list.
One researcher argues that the pharmaceutical industry ought to pay greater heed to such risks during drug development.
Research shows that increased consumption of coffee and cannabis may reduce the risk for early death from hepatitis C infection.
A recent study analyzed health outcomes among those with decompensated cirrhosis treated with Sovaldi-based regimens.
A frank talk about hepatic encephalopathy, including causes, treatments, and symptoms.
AZT and ddI were the main drugs associated with liver damage in a new study.
Can’t get enough of the Olympics? Read Karen Hoyt’s heartwarming account of her participation in the World Transplant Games.
This finding calls into question the importance of the one differentiation between alcoholic and non-alcoholic fatty liver disease.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.